<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="308275">
  <stage>Registered</stage>
  <submitdate>23/07/2009</submitdate>
  <approvaldate>4/08/2009</approvaldate>
  <actrnumber>ACTRN12609000657224</actrnumber>
  <trial_identification>
    <studytitle>Skin changes related to insulin therapy in type 1 diabetes</studytitle>
    <scientifictitle>Skin changes related to insulin therapy in type 1 diabetes</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Diabetes</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Prospective observational study of skin changes related to insulin therapy.
Patients will be seen at their routine 3 monthly clinic appointment. All patients will be invited to participate and have thier clinical risk factors assessed and invited to have a skin biopsy and intradermal tesing performed. Those with skin changes will have their clinical risk factors assessed, be asked to complete a short questionnaire about the impact that these skin changes have on their diabetes self manageemnt, and invited to have their skin changes photographed, a skin biopsy taken, intradermal skin testing, and patch testing.
This is not an interventional trial.</interventions>
    <comparator>Patients with and without skin changes will be compared</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>skin biopsy- Histological changes will be examined and summarised.</outcome>
      <timepoint>12 months after enrollment in the study.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>clinical risk factors- from clinical data (history, examination, blood tests) collected at routine clinical appointments prospectively</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>intradermal testing- skin reaction to insulin and the diluent insulin is mixed with</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>patch testing- skin reaction to the teflon cannula of the insulin pump</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>psychological impact of skin changes by questionnaire</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>known type 1 or 2 diabetes
understand the research protocol 
consent</inclusivecriteria>
    <inclusiveminage>5</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>moderate-severe eczema or other skin condition,</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Convenience sample</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/09/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>RNSH</primarysponsorname>
    <primarysponsoraddress>Pacific Highways
St Leonards
Sydney NSW 2065</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Royal North Shore Hospital (RNSH)</fundingname>
      <fundingaddress>Pacific Highways
St Leonards
Sydney NSW 2065</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Department of Endocrinology Diabetes Trust Fund</fundingname>
      <fundingaddress>Dr Greg Fulcher
Department of Endocrinology
RNSH St Leonards NSW 2065</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Skin changes such as lipohypertrophy and lipoatrophy affect around 20% of patients with Type 1 Diabetes Mellitus during the course of their illness. There has been very liitle previous research in this area. Little is know about the psychological impact of these changes, the pathophysiology of the changes, or the best treatment. The aim of this study is 1) to investigate  clinical, immunological and allergic factors that may be associated with these skin changes, 2) examine the histology of the skin (ie look at the structure of the skin under the microscope) and cells involved in lipodystrophic skin</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname />
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>17/06/2009</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Monique Stone</name>
      <address>Level 5 Douglas Building
RNSH
St Leonards NSW 2065</address>
      <phone>+61 2 9926 6904</phone>
      <fax />
      <email>stonem@med.usyd.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Monique Stone</name>
      <address>Level 5 Douglas Buidling
RNSH
St Loenards NSW 2065</address>
      <phone>+61 2 9926 6904</phone>
      <fax />
      <email>stonem@med.usyd.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>